-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CDE's official website shows that Quanxin Bio's class 1 new drug QX008N injection has obtained an implied license for clinical trials and is intended to be used for the treatment of asthma and chronic obstructive pulmonary disea.
Source: CDE official website
QX008N injection is a TSLP monoclonal antibody, TSLP receptor (TSLPR) is a member of the hematopoietic factor receptor family and is a type I cytokine receptor prote.
In December 2021, Tezepelumab, co-developed by Amgen and AstraZeneca, was approved by the FDA for additional maintenance therapy in children and adults with severe asthma 12 years and older, becoming the world's first approved monoclonal targeting human TSLP Antibody dru.
At present, no drug with the same target has been approved in China, but a number of products are in the clinical sta.
Founded in 2015, Quanxin Bio is a high-tech enterprise that develops and produces antibody drugs, focusing on the innovative development of antibody drugs for the treatment of severe chronic inflammation caused by autoimmunity and allergi.
Quanxin Bio has some Class 1 new drugs under development
Source: MED0 China Drug Evaluation Database
According to the data from Min.
Source: Minet database, CDE official website, e.